Goldman Sachs’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Goldman Sachs’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-199,680	Closed	-$6.79M	–	7354
2014 Q1	$6.79M	Sell	199,680 -143,890	-42%	-$4.92M	﹤0.01%	2715
2013 Q4	$6.56M	Buy	+343,570	New	+$6.25M	﹤0.01%	2779

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Goldman Sachs's CTIC Position: Q2 2023 in Review

Goldman Sachs sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 1,183,198 shares — an estimated $4.97M sold.

Goldman Sachs first reported a position in CTIC in Q2 2013 and held it in 31 quarters. The position peaked at $8.94M in Q3 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Goldman Sachs reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Goldman Sachs sold 1,183,198 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $4.97M.
Goldman Sachs first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and held it in 31 quarters.
Goldman Sachs's CTI BioPharma Corp. (DE) Common Stock position peaked at $8.94M in Q3 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Goldman Sachs's 13F filing for Q2 2023, filed 15 Aug 2023.